As a leader in providing traditional as well as state-of-the-art treatments and therapies for prostate cancer, Chesapeake Urology's Prostate Cancer Center was the lead clinical research site that led to FDA approval of SpaceOAR® Hydrogel System. The research trial was led by Chesapeake Urology prinicpal investigator, Dr. Richard Hudes, radiation oncologist.
SpaceOAR is a new application that helps prevent damage to the rectum due to potential "scatter" of radiation during radiation therapy for prostate cancer treatment. OAR stands for "Organs at Risk." By separating the prostate from the rectum, SpaceOAR Hydrogel may eliminate or reduce damage to the rectum from radiation therapy.
The outpatient procedure usually takes less than 30 minutes to inject the hydrogel. The procedure can be performed under anesthesia or local sedation.
How the SpaceOAR® Hydrogel System Works
SpaceOAR hydrogel is injected as a liquid between the prostate and rectum under ultrasound guidance. Once injected, the liquid solidifies within seconds into a hydrogel that pushes the rectum away from the prostate. The result is reduced rectal radiation during radiation therapy.
The hydrogel maintains space during radiation therapy and then liquefies, allowing it to be absorbed into the body and cleared from the body.
Pictured: Injected into the space between the rectm and the prostate, SpaceOAR hydrogel creates a stable space that moves the rectum to the lower dose region during radiotherapy.
SpaceOAR Hydrogel is made of two liquids that when combined form a soft gel-like synthetic material that is mostly made of water. Because of its water content it is called a hydrogel. Studies have shown that the material is biocompatible and can be used safely in the body.
Upon injection of the liquid, the hydrogel solidifies. SpaceOAR Hydrogel separates your prostate and rectum for about three months providing protection during radiation treatment and is naturally absorbed in approximately six months.